S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Experts: NVIDIA Now "Too Big to Succeed" (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Experts: NVIDIA Now "Too Big to Succeed" (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
The single greatest medical breakthrough of all time? (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Experts: NVIDIA Now "Too Big to Succeed" (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Experts: NVIDIA Now "Too Big to Succeed" (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
The single greatest medical breakthrough of all time? (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Experts: NVIDIA Now "Too Big to Succeed" (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Experts: NVIDIA Now "Too Big to Succeed" (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
The single greatest medical breakthrough of all time? (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Experts: NVIDIA Now "Too Big to Succeed" (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Experts: NVIDIA Now "Too Big to Succeed" (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
The single greatest medical breakthrough of all time? (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
NASDAQ:ARQT

Arcutis Biotherapeutics (ARQT) Stock Forecast, Price & News

$5.38
-0.33 (-5.78%)
(As of 09/22/2023 ET)
Compare
Today's Range
$5.28
$5.84
50-Day Range
$5.38
$10.98
52-Week Range
$5.28
$20.64
Volume
947,967 shs
Average Volume
977,316 shs
Market Capitalization
$331.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$43.43

Arcutis Biotherapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
707.2% Upside
$43.43 Price Target
Short Interest
Bearish
27.89% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.80mentions of Arcutis Biotherapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$11,299 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.77) to ($3.92) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

487th out of 965 stocks

Pharmaceutical Preparations Industry

219th out of 456 stocks


ARQT stock logo

About Arcutis Biotherapeutics (NASDAQ:ARQT) Stock

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical formulation of ivarmacitinib designed to reach deeper into the skin in order to treat alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

ARQT Price History

ARQT Stock News Headlines

The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Goldman Sachs Sticks to Its Buy Rating for Arcutis Biotherapeutics (ARQT)
JonesTrading Reaffirms Their Buy Rating on Arcutis Biotherapeutics (ARQT)
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk
I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.
Why Shares of Arcutis Biotherapeutics Fell This Week
Arcutis Appoints Interim Chief Financial Officer (CFO)
7 Analysts Have This to Say About Arcutis Biotherapeutics
JonesTrading Remains a Buy on Arcutis Biotherapeutics (ARQT)
See More Headlines
Receive ARQT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

ARQT Company Calendar

Last Earnings
8/08/2023
Today
9/24/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARQT
Fax
N/A
Employees
268
Year Founded
2016

Price Target and Rating

Average Stock Price Forecast
$43.43
High Stock Price Forecast
$57.00
Low Stock Price Forecast
$22.00
Forecasted Upside/Downside
+707.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-311,460,000.00
Net Margins
-2,837.94%
Pretax Margin
-2,837.94%

Debt

Sales & Book Value

Annual Sales
$3.69 million
Book Value
$3.44 per share

Miscellaneous

Free Float
48,892,000
Market Cap
$331.68 million
Optionable
Not Optionable
Beta
0.64

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Todd Franklin Watanabe M.A.Mr. Todd Franklin Watanabe M.A. (Age 55)
    Pres, CEO & Director
    Comp: $1.01M
  • Dr. Bhaskar Chaudhuri Ph.D. (Age 68)
    Co-Founder & Independent Director
    Comp: $59.67k
  • Mr. Masaru Matsuda Esq. (Age 52)
    J.D., Sr. VP, Gen. Counsel & Corp. Sec.
    Comp: $626.22k
  • Dr. Patrick E. Burnett M.D. (Age 51)
    Ph.D., Sr. VP & Chief Medical Officer
    Comp: $689.95k
  • Mr. John W. Smither CPA (Age 70)
    Interim CFO & Principal Accounting Officer
  • Ms. Patricia A. TurneyMs. Patricia A. Turney (Age 56)
    Sr. VP of Operations
  • Mr. Rajvir Madan
    Chief Digital & Technology Officer
  • Mr. Eric McIntyre
    Head of Investor Relations
  • Ms. Courtney Barton (Age 40)
    VP and Chief Compliance Officer & Privacy Officer
  • Ms. Amanda Sheldon
    Head of Corp. Communications













ARQT Stock - Frequently Asked Questions

Should I buy or sell Arcutis Biotherapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcutis Biotherapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARQT shares.
View ARQT analyst ratings
or view top-rated stocks.

What is Arcutis Biotherapeutics' stock price forecast for 2023?

6 Wall Street research analysts have issued 12-month price targets for Arcutis Biotherapeutics' stock. Their ARQT share price forecasts range from $22.00 to $57.00. On average, they expect the company's share price to reach $43.43 in the next twelve months. This suggests a possible upside of 707.2% from the stock's current price.
View analysts price targets for ARQT
or view top-rated stocks among Wall Street analysts.

How have ARQT shares performed in 2023?

Arcutis Biotherapeutics' stock was trading at $14.80 on January 1st, 2023. Since then, ARQT shares have decreased by 63.6% and is now trading at $5.38.
View the best growth stocks for 2023 here
.

Are investors shorting Arcutis Biotherapeutics?

Arcutis Biotherapeutics saw a drop in short interest during the month of August. As of August 31st, there was short interest totaling 12,480,000 shares, a drop of 19.2% from the August 15th total of 15,450,000 shares. Based on an average daily trading volume, of 1,100,000 shares, the short-interest ratio is presently 11.3 days. Approximately 27.9% of the company's shares are short sold.
View Arcutis Biotherapeutics' Short Interest
.

When is Arcutis Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our ARQT earnings forecast
.

How were Arcutis Biotherapeutics' earnings last quarter?

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) announced its earnings results on Tuesday, August, 8th. The company reported ($1.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.22) by $0.06. The business earned $5.19 million during the quarter, compared to analyst estimates of $4.87 million. Arcutis Biotherapeutics had a negative net margin of 2,837.94% and a negative trailing twelve-month return on equity of 188.88%.

What ETF holds Arcutis Biotherapeutics' stock ?

Virtus LifeSci Biotech Clinical Trials ETF holds 10,172 shares of ARQT stock, representing 0.89% of its portfolio.

What other stocks do shareholders of Arcutis Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcutis Biotherapeutics investors own include Black Diamond Therapeutics (BDTX), Pfizer (PFE), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Applied Therapeutics (APLT), Aptinyx (APTX), BioNTech (BNTX), ServiceNow (NOW), Qualys (QLYS) and AbbVie (ABBV).

When did Arcutis Biotherapeutics IPO?

(ARQT) raised $125 million in an initial public offering (IPO) on Friday, January 31st 2020. The company issued 7,800,000 shares at $15.00-$17.00 per share. Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO and Cantor was co-manager.

What is Arcutis Biotherapeutics' stock symbol?

Arcutis Biotherapeutics trades on the NASDAQ under the ticker symbol "ARQT."

Who are Arcutis Biotherapeutics' major shareholders?

Arcutis Biotherapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include State Street Corp (8.48%), Rubric Capital Management LP (7.92%), Jennison Associates LLC (6.99%), BlackRock Inc. (6.86%), Polar Capital Holdings Plc (5.07%) and Marshall Wace LLP (3.76%). Insiders that own company stock include Bhaskar Chaudhuri, David W Osborne, Howard G Welgus, Howard G Welgus, John W Smither, Masaru Matsuda, Orbimed Advisors Llc, Patricia A Turney, Patrick Burnett, Scott L Burrows and Todd Franklin Watanabe.
View institutional ownership trends
.

How do I buy shares of Arcutis Biotherapeutics?

Shares of ARQT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcutis Biotherapeutics' stock price today?

One share of ARQT stock can currently be purchased for approximately $5.38.

How much money does Arcutis Biotherapeutics make?

Arcutis Biotherapeutics (NASDAQ:ARQT) has a market capitalization of $331.68 million and generates $3.69 million in revenue each year. The company earns $-311,460,000.00 in net income (profit) each year or ($5.54) on an earnings per share basis.

How many employees does Arcutis Biotherapeutics have?

The company employs 268 workers across the globe.

How can I contact Arcutis Biotherapeutics?

Arcutis Biotherapeutics' mailing address is 2945 TOWNSGATE ROAD SUITE 110, WESTLAKE VILLAGE CA, 91361. The official website for the company is www.arcutis.com. The company can be reached via phone at 805-418-5006 or via email at ir@arcutis.com.

This page (NASDAQ:ARQT) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -